Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 76 to 100 of 746

TitleReference numberPublishedLast updated
Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve diseaseIPG769
Afamelanotide for treating erythropoietic protoporphyriaHST27
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancerTA911
KardiaMobile for detecting atrial fibrillationMTG64
Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)TA910
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancerTA909
AI-derived computer-aided detection (CAD) software for detecting and measuring lung nodules in CT scan imagesDG55
Irreversible electroporation for treating prostate cancerIPG768
Rimegepant for preventing migraineTA906
Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapyTA908
Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retentionIPG766
Radiofrequency denervation for osteoarthritic knee painIPG767
Deucravacitinib for treating moderate to severe plaque psoriasisTA907
Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an optionIPG764
Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young peopleIPG765
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fractionTA902
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancerTA903
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Upadacitinib for previously treated moderately to severely active Crohn's diseaseTA905
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Tixagevimab plus cilgavimab for preventing COVID-19TA900
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist careDG48
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895

Results per page

  1. 10
  2. 25
  3. 50
  4. All